Immatics biotechnologies, a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer, today announces that it has received €22m to complete a Series D financing round
Credit: Gorodenkoff/Shutterstock
We round up the latest laboratory software tools to help streamline laboratory operations in 2023
Credit: Larichshutterstock/Shutterstock
We round up the latest cluster management software tools available to scientists and researchers using HPC
Credit: raigvi/Shutterstock
A round-up of the latest processing and memory technologies
